Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.59
-0.05 (-0.65%)
At close: May 18, 2026, 4:00 PM EDT
7.59
0.00 (0.00%)
After-hours: May 18, 2026, 4:10 PM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Seres Therapeutics stock has a target of 22, which predicts a 189.86% increase from the current stock price of 7.59.
Price Target: $22 (+189.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Seres Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +189.86% | Mar 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $22 | Strong Buy | Maintains | $14 → $22 | +189.86% | Sep 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -20.95% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +229.38% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | +97.63% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
n/a
from 789.00K
Revenue Next Year
n/a
EPS This Year
-8.39
from 0.64
EPS Next Year
-9.35
from -8.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -8.64 | -9.63 | |
| Avg | -8.39 | -9.35 | |
| Low | -8.07 | -8.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.